Federated Hermes Inc. Cuts Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Federated Hermes Inc. decreased its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 90.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 82,067 shares of the company's stock after selling 824,720 shares during the period. Federated Hermes Inc. owned approximately 0.06% of MiMedx Group worth $789,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. IMG Wealth Management Inc. acquired a new position in MiMedx Group in the 4th quarter worth about $28,000. SkyView Investment Advisors LLC increased its stake in shares of MiMedx Group by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company's stock valued at $77,000 after buying an additional 3,000 shares during the period. Principal Financial Group Inc. raised its holdings in MiMedx Group by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company's stock valued at $328,000 after buying an additional 3,292 shares during the last quarter. Bank of New York Mellon Corp boosted its position in MiMedx Group by 0.7% during the 4th quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company's stock worth $4,849,000 after buying an additional 3,300 shares during the period. Finally, Van ECK Associates Corp bought a new stake in MiMedx Group during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 79.15% of the company's stock.

Insiders Place Their Bets

In other MiMedx Group news, CAO William Frank Iv Hulse sold 81,446 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the completion of the sale, the chief accounting officer now directly owns 494,774 shares in the company, valued at approximately $3,859,237.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the transaction, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. This represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 144,018 shares of company stock worth $1,130,312. 1.30% of the stock is owned by corporate insiders.

MiMedx Group Trading Down 1.9 %

NASDAQ MDXG traded down $0.13 during mid-day trading on Monday, reaching $6.55. 382,073 shares of the stock were exchanged, compared to its average volume of 693,551. The stock has a market cap of $965.25 million, a P/E ratio of 11.91 and a beta of 1.74. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The stock has a 50 day simple moving average of $7.66 and a 200-day simple moving average of $8.04.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. On average, analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on MDXG shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com downgraded MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, April 16th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.